United States Drug Delivery Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

United States Drug Delivery Devices Market Trends and Insights

Rising Prevalence of Chronic Diseases

Nearly 38.4 million Americans lived with diagnosed diabetes in 2024, and the CDC projects one in three adults will carry the diagnosis by 2050, intensifying long-term demand for continuous glucose monitors, insulin pumps, and GLP-1 autoinjectors.^{[1]Centers for Disease Control and Prevention, “National Diabetes Statistics Report 2024,” cdc.gov} Cancer incidence surpassed 2 million new cases in 2024, sustaining high utilisation of port-a-cath systems and ambulatory infusion pumps for chemotherapy. Cardiovascular disease affects 127 million adults, prompting increased use of anticoagulant pens and drug-eluting stents that mitigate hospital readmissions. Chronic respiratory conditions and a growing autoimmune population are driving the United States drug delivery devices market toward durable, patient-managed formats. The cumulative effect is a multiyear lift in baseline procedure volumes, supporting predictable unit shipments well beyond the forecast horizon.

Growing Preference for Self-Administration & Home Healthcare

CMS introduced stand-alone reimbursement codes for home infusion therapy in 2025, neutralising historical payment penalties and giving providers an economic incentive to discharge stable patients with wearable injectors and connected pumps.^{[2]Centers for Medicare & Medicaid Services, “Home Infusion Therapy Payment Rule 2025,” cms.gov} Medicare Advantage enrollment crossed 33 million members the same year, and plans rapidly bundled device supplies with telehealth monitoring to cut emergency-department visits. The American Nurses Association forecasts 78,000 unfilled RN positions by 2026, further encouraging technologies that shift dosing responsibility to patients. Device makers answered with user-centred autoinjectors featuring needle-retraction windows and audible cues that reduce error rates among seniors. Collectively, these trends pivot the United States drug delivery devices market toward home-centric care pathways that reward simplicity and remote visibility.

Connected Smart Devices Improve Adherence & Outcomes

Dexcom’s G7 CGM seamlessly links with Tandem’s Mobi pump, automatically modulating basal rates and reducing severe hypoglycemia events by 40% in a real-world cohort.^{[3]Dexcom Inc., “G7 Clinical Outcomes Presentation 2025,” dexcom.com} Propeller Health inhaler sensors transmit timestamped actuations and GPS data so pulmonologists can intervene before an asthma crisis, yet only connected devices with demonstrated clinical benefit are gaining broad reimbursement. Payers such as UnitedHealthcare now require documentation that closed-loop systems outperform manual therapy, forcing lagging device platforms to retrofit connectivity or risk exclusion. The FDA cybersecurity guidance issued in 2024 embedded SBOM submission as a premarket requirement, adding compliance costs but also establishing trust that data-rich devices will not expose networks. The net effect is a premium on platforms that transform raw data into actionable dosing logic, reinforcing digital moats around incumbents.

Biologics Capacity Boom Drives Demand for Advanced Containers

Manufacturers announced USD 150 billion in new U.S. biologics facilities between 2024-2025, with capacity to be concentrated in North Carolina, Indiana, and Ohio. Each monoclonal antibody batch requires cyclic olefin polymer syringes, elastomeric stoppers, and safety-engineered needles that comply with ISO 11608, propelling component backlogs beyond 18 months. West Pharmaceutical reported 24-month lead times for coated plungers in 2025, compelling drug sponsors to lock multiyear contracts early. Wearable injectors capable of handling 10-50 mL viscous formulations are simultaneously replacing IV infusion lines, shifting revenue from acute-care equipment into ambulatory patches. In the United States drug delivery devices market, container shortages have quietly become a rate-limiting step for therapy launches, advantaging vertically integrated suppliers.

Stringent FDA Regulatory Requirements

Cybersecurity guidance released in 2024 makes an SBOM and threat-modeling dossier a condition of clearance for any wireless device, extending development cycles 6-12 months and adding USD 2-5 million per platform. Combination product reviews now require human factors validation even when predicate devices exist, and post-market surveillance reporting is mandatory within 30 days of serious incidents. Smaller innovators struggle with the staffing and documentation load, slowing pipeline velocity and nudging the United States drug delivery devices industry toward consolidation. Real-world evidence is also becoming increasingly important; products must demonstrate performance in routine practice within 24 months, which escalates launch costs.

Recalls & Device Malfunctions Undermine Confidence

Medtronic’s Class I recall of over 2 million MiniMed pumps in 2024 shook patient trust and inflated liability premiums by 22% for all pump makers. Tandem and Insulet faced software-related recalls that year, and BD withdrew syringe lots due to particulate contamination alarms. Endocrinologists reported a 15% uptick in requests to switch back to manual injections during recall peaks, a behavioural drag on automated-device adoption. Class-action litigation raised out-of-pocket settlement costs and spurred payers to insist on longer warranty terms, trimming gross margins. The episode underscores how a single high-visibility failure can ripple across the broader United States drug delivery devices market for several quarters.

Segment Analysis

By Device Type: Injectable Platforms Dominate, Oral Systems Accelerate

Injectable platforms generated 43.27% revenue in 2025, anchoring the United States drug delivery devices market share with 8.2 billion units shipped. Wearable injectors such as BD Libertas and Enable enFuse now handle 5-50 mL biologics, opening subcutaneous routes for therapies once limited to infusion chairs. Oral controlled-release systems, although only 18% of 2025 revenue, will outpace all categories at 7.32% CAGR to 2031 because Rybelsus proved peptides can survive GI transit when paired with absorption enhancers. 

The historical CAGR for injectables averaged 5.8% during 2019-2025, but steps up slightly over 2026-2031 as biosimilar launches and GLP-1 demand intensify. Smart sensors improved adherence, but adoption lags pending uniform payer coverage. Transdermal and ocular devices together remain below 10% share but win premium pricing where they reduce clinic visits, exemplified by Genentech’s twice-yearly Susvimo refills for AMD. 

Note: Segment shares of all individual segments available upon report purchase

By Route of Administration: Intravenous Leads, Subcutaneous Surges

Intravenous delivery captured 36.83% of the 2025 value, primarily through hospital chemotherapy and TPN volumes, yet its forecast CAGR tails at 5.2% as payers reroute suitable biologics to the home. Subcutaneous delivery will grow 7.69% annually, driven by the scaling of large-volume patch pumps reimbursed under new home-infusion codes. Intradermal remains niche, though microneedle vaccine patches secured Breakthrough Device status in 2024. Oral routes hold a stable base, while pulmonary and transdermal routes serve targeted populations like COPD and chronic pain, sustaining mid-single-digit growth. 

By Application: Oncology Dominates, Diabetes Accelerates

Oncology retained 28.88% of 2025 spend thanks to infusion hardware, but diabetes devices will post the strongest 9.01% CAGR through 2031 as closed-loop ecosystems penetrate both Medicare and commercial formularies. Respiratory, cardiovascular, and autoimmune segments follow with steady growth tied to uptake of biologics or smart inhalers. Other categories, including rare-disease gene therapies, remain small in dollars but command ultra-high device ASPs due to cryogenic handling needs. 

Note: Segment shares of all individual segments available upon report purchase

By End User: Hospitals Lead, Home-Healthcare Gains Ground

Hospitals consumed 49.28% of 2025 expenditures, yet growth slowed to 4.9% as staffing shortages and value-based penalties encouraged earlier discharge. Home healthcare grows 8.78% annually after reimbursement parity, with ambulatory surgical centers and specialty clinics filling the mid-acuity gap. Devices that seamlessly transition across sites now enjoy procurement preference, meaning a single SKU must satisfy both institutional and home-care safety protocols. 

Geography Analysis

Regional demand in the United States drug delivery devices market aligns with payer mix and manufacturing footprints. North Carolina, Indiana, and Ohio host multibillion-dollar expansions in biologics production by Novo Nordisk, Eli Lilly, and Amgen, stimulating local supply chains for prefilled syringes and elastomeric seals. California and Massachusetts lead in clinical trials, driving the adoption of prototype devices among academic centres. Sun Belt states show the fastest unit growth as Medicare Advantage penetration tops 50% and diabetes prevalence rises. Rural broadband gaps still slow connected-device uptake in Mountain West counties; federal infrastructure funding should close most of that divide by 2028. State Medicaid policies create patchwork access: Texas expanded CGM coverage in 2025, boosting shipments 22%, whereas non-expansion states lag.